4-deoxybostrycin and Liver-Neoplasms

4-deoxybostrycin has been researched along with Liver-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for 4-deoxybostrycin and Liver-Neoplasms

Article	Year
Synthesis and antitumor activities of derivatives of the marine mangrove fungal metabolite deoxybostrycin. Marine drugs, 2012, Nov-30, Volume: 10, Issue:12 Deoxybostrycin (1) is an anthraquinone compound derived from the marine mangrove fungus Nigrospora sp. No. 1403 and has potential to be a lead for new drugs because of its various biological properties. A series of new derivatives (2-22) of deoxybostrycin were synthesized. The in vitro cytotoxicity of all the new compounds was tested against MDA-MB-435, HepG2 and HCT-116 cancer cell lines. Most of the compounds exhibit strong cytotoxicity with IC₅₀ values ranging from 0.62 to 10 μM. Compounds 19, 21 display comparable cytotoxicity against MDA-MB-435 to epirubicin, the positive control. The primary screening results indicate that the deoxybostrycin derivatives might be a valuable source of new potent anticancer drug candidates. Topics: Anthraquinones; Antineoplastic Agents; Ascomycota; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Epirubicin; Female; HCT116 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms	2012

Article

Year

Synthesis and antitumor activities of derivatives of the marine mangrove fungal metabolite deoxybostrycin.

Marine drugs, 2012, Nov-30, Volume: 10, Issue:12

Deoxybostrycin (1) is an anthraquinone compound derived from the marine mangrove fungus Nigrospora sp. No. 1403 and has potential to be a lead for new drugs because of its various biological properties. A series of new derivatives (2-22) of deoxybostrycin were synthesized. The in vitro cytotoxicity of all the new compounds was tested against MDA-MB-435, HepG2 and HCT-116 cancer cell lines. Most of the compounds exhibit strong cytotoxicity with IC₅₀ values ranging from 0.62 to 10 μM. Compounds 19, 21 display comparable cytotoxicity against MDA-MB-435 to epirubicin, the positive control. The primary screening results indicate that the deoxybostrycin derivatives might be a valuable source of new potent anticancer drug candidates.

Topics: Anthraquinones; Antineoplastic Agents; Ascomycota; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Epirubicin; Female; HCT116 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms

2012